

Joseph J Park

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7808708/publications.pdf>

Version: 2024-02-01

21
papers

223
citations

1307366

7
h-index

1058333

14
g-index

21
all docs

21
docs citations

21
times ranked

441
citing authors

#	ARTICLE	IF	CITATIONS
1	MHC Class I Limits Hippocampal Synapse Density by Inhibiting Neuronal Insulin Receptor Signaling. <i>Journal of Neuroscience</i> , 2014, 34, 11844-11856.	1.7	49
2	A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. <i>European Urology Oncology</i> , 2021, 4, 464-472.	2.6	39
3	Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer. <i>Acta Oncol</i> , 2017, 56, 1746-1753.	0.8	38
4	Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. <i>BJU International</i> , 2021, 128, 196-205.	1.3	18
5	Interleukin-6 expands homeostatic space for peripheral T cells. <i>Cytokine</i> , 2013, 64, 532-540.	1.4	16
6	PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 388-396.	2.0	15
7	Expression and alternative splicing of classical and nonclassical MHCI genes in the hippocampus and neuromuscular junction. <i>Molecular and Cellular Neurosciences</i> , 2016, 72, 34-45.	1.0	11
8	Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2022, 20, e440-e452.	0.9	10
9	Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	10
10	Immunotherapy in metastatic sarcomatoid renal cell carcinoma: A single institution experience. <i>Cancer Treatment and Research Communications</i> , 2020, 25, 100251.	0.7	5
11	Phase Ib/II study of durvalumab and guadecitabine in advanced kidney cancer Big Ten Cancer Research Consortium BTCRC GU16-043.. <i>Journal of Clinical Oncology</i> , 2021, 39, 328-328.	0.8	4
12	Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 165-175.	0.9	4
13	Association of prior local therapy and outcomes with programmed death ligand 1 inhibitors in advanced urothelial cancer. <i>BJU International</i> , 2022, 130, 592-603.	1.3	3
14	Association of time to second-line (2L) immune-checkpoint inhibitors (ICI) and outcomes with ICIs in patients (pts) with advanced urothelial carcinoma (aUC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 505-505.	0.8	1
15	Immune checkpoint inhibitors (ICI) in advanced upper tract and lower tract urothelial carcinoma (UC): A comparison of outcomes.. <i>Journal of Clinical Oncology</i> , 2021, 39, 406-406.	0.8	0
16	Association between prior radical surgery (RS) and outcomes with immune checkpoint inhibitor (ICI) therapy for advanced urothelial carcinoma (aUC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 444-444.	0.8	0
17	Outcomes of patients (pts) with advanced urothelial carcinoma (aUC) treated with immune checkpoint inhibitors (ICIs): Associations with age, race, sex and smoking history.. <i>Journal of Clinical Oncology</i> , 2021, 39, e16526-e16526.	0.8	0
18	Immune checkpoint inhibitors (ICI) in advanced sarcomatoid renal cell carcinoma (sRCC): A multicenter study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4568-4568.	0.8	0

#	ARTICLE	IF	CITATIONS
19	Implications of androgen receptor (AR) alterations identified by genomic testing of tissue and blood from advanced prostate cancer (aPC) patients (pts).. Journal of Clinical Oncology, 2022, 40, 138-138.	0.8	0
20	DNA damaging therapies in patients (pts) with prostate cancer (PC) and pathogenic alterations in homologous recombination repair (HRR) genes.. Journal of Clinical Oncology, 2022, 40, 129-129.	0.8	0
21	Biomarker-directed therapy in black and white men with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2022, 40, 5013-5013.	0.8	0